Recommendations for Systemic Therapy for Recurrent Malignant Gliomas

All members of the workgroup support the adoption of NCCN and ESMO guidelines.

There is currently no established systemic therapy for recurrent malignant glioma. For patients with good PS, reasonable chemotherapy options include temozolomide, lomustine, combination PCV, cyclophosphamide, platinum-based agents and irinotecan.

Bevacizumab, as monotherapy or in combination with other chemotherapy, may also be considered in recurrent glioblastoma.

For patients with poor PS, best supportive care is reasonable.

The SCAN workgroup acknowledges that there is no local data on systemic therapy in recurrent high-grade glioma.